Clinuvel Pharmaceuticals (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.
Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.
Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.
The company's shares slipped 2% in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。